Joseph McEvoy, MD

Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities

Background: Tardive dyskinesia (TD) is managed by dose reduction or interruption of dopamine-receptor antagonists (DRAs), possibly causing psychiatric disorder relapse. Deutetrabenazine (...

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Fredrick Jarskog , MD;

Rajeev Kumar , MD, FRCPC, CMD, FACP;

Karen Anderson , MD;

Joseph McEvoy , MD;

Hubert Fernandez , MD;

Stanislaw Ochudlo , MD, PhD;

03/01/2019

Long-term Improvements in Site-Rated Outcomes With Deutetrabenazine Treatment in Patients With Tardive Dyskinesia

Background: Tardive dyskinesia (TD) is a movement disorder that may intensify the stigma of patients with psychiatric disorders. In the ARM-TD and AIM-TD trials (parent studies), deutetra...

Nicholas Gross , MS;

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Rajeev Kumar , MD, FRCPC, CMD, FACP;

Joseph McEvoy , MD;

Fredrick Jarskog , MD;

Karen Anderson , MD;

Stanislaw Ochudlo , MD, PhD;

Hubert Fernandez , MD;

03/01/2019

Effect of Tardive Dyskinesia on Quality of Life: Patient-Reported Symptom Severity Is Associated With Physical, Mental, and Social Functioning Deficits

Background: Tardive dyskinesia (TD), an often-irreversible movement disorder typically caused by exposure to antipsychotics, most commonly affects the face, mouth, and tongue, and may be ...

Avery Rizio , PhD;

Jakob Bjorner , MD, PhD;

Stephen Maher , PhD;

Mark Kosinski , DPM, FIDSA, MA;

Sanjay K. Gandhi , MD, PhD;

Joseph McEvoy , MD;

Benjamin Carroll , PharmD;

03/01/2019